Pfizer’s metastatic colorectal cancer (mCRC) combination therapy has met one of the primary endpoints of improving progression-free survival (PFS) in a Phase III trial, further supporting a full ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

Scientists Discover How Excessive Red Meat Consumption Increases Colorectal Cancer Risk Oct. 23, 2024 — Scientists have uncovered a critical link between the overconsumption of red meat and an ...

Scientists from the Cancer Dependency Map (DepMap) at the Broad Institute of MIT and Harvard and Columbia University have ...

Aspirin reduced colorectal cancer recurrence risk by 50% in patients with PIK3CA mutations over three years. Mutations in the PI3K pathway predict aspirin response, broadening its use to more patients ...

Please provide your email address to receive an email when new articles are posted on . Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations ...

Daily low-dose aspirin can help prevent cancers from returning in about a third of colon cancer patients, a new study says. Taking 160 milligrams of aspirin a day cuts the risk of cancer ...

A specific variety of Corfiot olive oil is taking part in a scientific study on colon cancer – The research was conducted by Louisiana State University, and the results were published in Nutrients ...

The KRAS G12C mutation is present in approximately 3-5% of colorectal cancers. Price Action: Amgen stock is up 0.99% at $272.11 at last check Friday.

Pfizer (PFE) announced positive topline results from the progression-free survival – PFS – analysis of the Phase 3 BREAKWATER study of Braftovi ...